OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point the prognosis is poor. Current standard of care therapies focus on debulking surgery and platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard. The majority of patients respond well to initial first-line therapy and enter into remission, however over 80% of patients will relapse and require multiple lines of therapy.

For many years the ovarian cancer drug market has been fairly stagnant, mainly due to the high use of generics and the lack of successful development of new innovative therapies. However, with the recent approvals of Avastin and the PARP inhibitors Lynparza (olaparib), Rubraca (rucaparib), and Zejula (niraparib), the market is beginning to diversify. New understanding of the heterogeneity and biology of ovarian cancer has led to the active development of new targeted therapies, immuno-oncology (IO) drugs, and next-generation chemotherapies. A greater understanding of the tumor microenvironment is expected to occur over the forecast period, which is anticipated to further drive the successful development of new patient-specific therapies. GlobalData is predicting a total of 9 new entrants to launch over the forecast period from 2015-2025. Competition will be particularly fierce amongst PARP inhibitors as they continue to establish their place in the treatment paradigm of ovarian cancer.
Key Questions Answered
How will the ovarian cancer market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) change from 2015–2025?
What are the most promising late-stage pipeline drugs in ovarian cancer?
How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
What are the unmet needs in ovarian cancer treatment management?
What drivers and barriers will affect ovarian cancer therapeutics sales in the 7MM over the forecast period?


Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline ovarian cancer market revenue from 2015–2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM ovarian cancer therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ovarian cancer therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

AB Science
Array BioPharma
Boehringer Ingelheim
Bristol-Myers Squibb
Chugai Pharmaceutical
Clovis Oncology
Innate Pharma
Mateon Therapeutics
Merck & Co.
Merck KGaA
Oncolytics Biotech
Ono Phamaceutical
Prima BioMed
PsiOxus Therapeutics
Taiho Pharmaceutical

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Ovarian Cancer: Executive Summary

2.1 Dramatic Growth, Driven by the Establishment of Standard of Care Maintenance Therapies, Is Projected for the 7MM Ovarian Cancer Market from 2015 to 2025

2.2 AstraZeneca, Tesaro, and Clovis are Poised for a Showdown in the PARP Inhibitor Ovarian Cancer Treatment Market for BRCA+, BRCA-like, and All Comers

2.3 Roche Expected to Remain Market Leader on the Heels of Avastin-based Combinations and the 7MM’s Second Programmed Death-Ligand 1 Inhibitor, Tecentriq, to Compete with Merck KGaA/Pfizer’s First-to-Market Bavencio

2.4 Unmet Need of More Therapies for Recurrent Patients in Later Lines of Therapy, Especially Platinum-Resistant Patients, Anticipated to be Partially Fulfilled, with Opportunities Remaining

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.2 Staging Systems

4.3 Risk Factors, Symptoms, and Screening

4.4 Prognosis and Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global Trends

5.3.1 7MM Incidence Trends

5.3.2 7MM Trends in Relative Survival

5.4 Forecast Methodology

5.4.1 Sources Used Tables

5.4.2 Forecast Assumptions and Methods

5.4.3 Sources Not Used

5.5 Epidemiological Forecast for Ovarian Cancer (2015–2025)

5.5.1 Diagnosed Incident Cases of Ovarian Cancer

5.5.2 Age-Specific Diagnosed Incident Cases of Ovarian Cancer

5.5.3 Age-Standardized Diagnosed Incidence of Ovarian Cancer

5.5.4 Diagnosed Incident Cases of Primary Peritoneal Cancer

5.5.5 Five-Year Diagnosed Prevalent Cases of Ovarian Cancer and Primary Peritoneal Cancer

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Current Treatment Options

6.1 Overview

6.2 Diagnosis and Treatment

6.2.1 Diagnosis

6.2.2 Treatment Guidelines

6.3 Clinical Practice and Leading Prescribed Drugs

6.4 Product Profiles – Major Brands, Angiogenesis Inhibitors

6.4.1 Avastin (bevacizumab)

6.5 Product Profiles – Major Brands, PARP Inhibitors

6.5.1 Lynparza (olaparib)

6.5.2 Rubraca (rucaparib)

6.5.3 Zejula (niraparib)

6.6 Product Profiles – Major Brands, Next-Generation Chemotherapies

6.6.1 Yondelis (trabectedin)

6.7 Generic Chemotherapy

6.7.1 Front-Line Treatment (Adjuvant/First Line)

6.7.2 Recurrent Disease

7 Unmet Needs Assessment and Opportunity Analysis

7.1 Overview

7.2 Improved First-line Therapies

7.2.1 Unmet Need

7.2.2 Gap Analysis

7.2.3 Opportunity

7.3 Alternative Treatment Options for Platinum-Refractory/Resistant Patients

7.3.1 Unmet Need

7.3.2 Gap Analysis

7.3.3 Opportunity

7.4 Individualized Treatment Approaches

7.4.1 Unmet Need

7.4.2 Gap Analysis

7.4.3 Opportunity

7.5 Therapy Option for Histological Subtypes Beyond High-Grade Serous Ovarian Cancer

7.5.1 Unmet Need

7.5.2 Gap Analysis

7.5.3 Opportunity

7.6 An Early Stage Diagnostic for Ovarian Cancer

7.6.1 Unmet Need

7.6.2 Gap Analysis

7.6.3 Opportunity

8 Research and Development Strategies

8.1 Overview

8.1.1 Optimizing Chemotherapy

8.1.2 Targeted Therapies – A Patient Specific Approach

8.1.3 Immunotherapies – A Patient Specific Approach

8.1.4 Combination Therapies

8.1.5 Licenses and Alliances

8.2 Clinical Trial Design

8.2.1 Current Clinical Trial Endpoints

8.2.2 The Future of Clinical Trial Endpoints

8.2.3 Moving Beyond the Current Platinum Sensitive/Resistant Paradigm for Patient Recruitment in Recurrent Clinical Trials

9 Pipeline Assessment

9.1 Overview

9.2 Product Profiles – Immune Checkpoint Modulators

9.2.1 Bavencio (avelumab)

9.2.2 Opdivo (nivolumab)

9.2.3 Tecentriq (atezolizumab)

9.3 Product Profiles – Cancer Vaccines

9.3.1 Vigil (gemogenovatucel-T)

9.4 Product Profiles – Vascular Disrupting Agents

9.4.1 Fosbretabulin tromethamine

9.5 Product Profiles – PARP Inhibitors

9.5.1 Veliparib

9.6 Product Profiles – Targeted Cytotoxic Therapies (Antibody-Drug Conjugates)

9.6.1 Mirvetuximab soravtansine

9.7 Product Profiles – Next-Generation Chemotherapies

9.7.1 Opaxio (paclitaxel poliglumex)

9.7.2 Lurbinectedin

9.7.3 Apealea/Paclical (paclitaxel)

9.8 Innovative Early Stage Approaches

9.8.1 Immune Checkpoint Modulators

9.8.2 Oncolytic Viruses

9.8.3 Angiogenesis Inhibitors

9.8.4 Interleukin-12 Agonists

9.8.5 Toll-Like Receptor 8 Agonists

9.8.6 Cancer Vaccines

9.8.7 Kinase Inhibitors

9.8.8 Targeted Cytotoxic Therapies

9.8.9 P53 Agonists

9.9 Other Notable Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Products

10.2 Commercial Benchmark of Key Pipeline Therapies

10.3 Competitive Assessment

10.4 Top-Line Ten-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.4 Forecasting Methodology

11.4.1 Percentage of Drug-Treated Patients

11.4.2 Drugs Included in Each Therapeutic Class

11.4.3 Launch and Patent Expiry Dates

11.4.4 General Pricing Assumptions

11.4.5 Average Body Weight and Surface Area Across the 7MM

11.4.6 General Forecast Assumptions

11.4.7 Individual Drug Assumptions

11.4.8 Generic and Biosimilar Erosion

11.4.9 Pricing of Pipeline Agents

11.5 Primary Research

11.5.1 Physicians and Specialists Included in This Study

11.5.2 Online Survey of High-Prescribing Physicians

11.6 About the Authors

11.6.1 Analysts

11.6.2 Epidemiologist

11.6.3 Therapy Area Director

11.6.4 Global Director of Therapy Analysis and Epidemiology

11.6.5 Global Head of Healthcare

11.7 About GlobalData

11.8 Contact Us

11.9 Disclaimer

Frequently asked questions

OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025 thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Oncology reports
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025 in real time.

  • Access a live OpportunityAnalyzer: Ovarian Cancer – Opportunity Analysis and Forecasts to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.